At the news
? BEARISHIMPACT 7/10 8-K filed May 5, 2026 at 16:08 ET
Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, missing consensus of $0.74 by 40.5%, despite 10% YoY revenue growth to $58.8M. Net income declined 24% YoY to $8.7M, and the company maintained its full-year revenue guidance of $275-290M. The miss was driven by higher R&D and SG&A costs, overshadowing strong product sales growth.
- Q1 2026 total revenues: $58.8M (up 10% YoY from $53.3M)
- Net product sales: $54.9M (up 26% YoY)
- GAAP diluted EPS: $0.44 vs consensus $0.74 (40.5% miss)
- Net income: $8.7M vs $11.4M in Q1 2025 (down 24%)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access